Please assess the completion status of the following clinical trial:

Trial Title: Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Migraine headache (International Classification of Headache Disorders 3B criteria)~Exclusion Criteria:~* Brain imaging ordered~* Fever~* Objective neurological findings~* Pregnancy/ breast feeding~* Allergy/ contraindication to investigational medication~* History of addiction to opioids, use of methadone, any use of opioids previous 30 days

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydromorphone (Type: ACTIVE_COMPARATOR): Hydromorphone 1mg, administered as intravenous drip over 5 minutes. Patients can receive second 1mg dose at 1 hour.
- Prochlorperazine (Type: ACTIVE_COMPARATOR): Prochlorperazine 10mg, administered as intravenous drip over 5 minutes. Diphenhydramine 25mg co-administered.~Patients can receive second 10mg dose at 1 hour.

Based on this trial design, predict the completion outcome and termination type (if applicable).